Glenmark Pharmaceuticals to Directly Commercialise RYALTRIS® in the U.S., Expanding Innovative Portfolio

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced that it will manage end-to-end commercialization and distribution for RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray in the United States, effective April 1, 2026. This move marks a significant step in Glenmark’s continued expansion in the region with a sustainable approach to building a strong, direct commercial U.S. based presence. RYALTRIS®, launched in the U.S. in 2022, is approved by the U.S. Food and Drug Administration for the treatment of symptoms associated with Seasonal Allergic Rhinitis in adults and paediatric patients 12 years of age and older. Glenmark will directly lead brand strategy, market access, and customer engagement for RYALTRIS® in the U.S., allowing for more focused execution and closer alignment with healthcare providers and patients.